beta lactam monotherapy
DISEASE INTERVENTION COMPARISON RESULTS
J Antimicrob Chemother. 2006 Apr;57(4):639-47 Meta-Analysis
IN endocarditis, bacterial, Staphylococcus aureus, Streptococcus viridans The Use of
beta lactam monotherapy
As Treatment, Acute
Is equal Than
beta lactam plus aminoglycoside combination therapy
To modify mortality, treatment failure or relapse. More nephrotoxicity when adding aminoglycosides.
Cochrane Database Syst Rev. 2010;11:CD005197 Systematic Review, Cochrane Review
IN neutropenia, chemotherapy induced, febrile, empirical antibiotics The Use of
beta lactam monotherapy with anti-pseudomonal drugs, piperacillin-tazobactam
As Treatment, Acute
Is undefined Than
other beta-lactams antibiotics
To reduce the risk of death (RR 0.56). Carbapenems had same mortality and less clinical failure but more C. difficile superinfections
Cochrane Database Syst Rev. 2006;(1):CD003344 Systematic Review, Cochrane Review
IN sepsis The Use of
beta lactam monotherapy , empirical antibiotics
As Treatment, Acute
Is better Than
beta lactam plus aminoglycoside combination therapy
To improve global outcome: no differences in mortality or clinical failure, but less nephrotoxicity (RR 0.30) than aminoglycosides combination.
BMJ. 2004 Mar 20;328(7441):668 Meta-Analysis
IN sepsis The Use of
empirical antibiotics, beta lactam monotherapy
As Treatment, Acute
Is better Than
beta lactam plus aminoglycoside combination therapy
To reduce the risk for adverse events (nephrotoxicity ) and reduce the risk of clinical failure, while no difference in all cause fatality